Successful treatment of refractory low grade duodenal lymphoma with rituximab, an anti-CD20 monoclonal antibody.
Ahmed, Shazia
Successful treatment of refractory low grade duodenal lymphoma with rituximab, an anti-CD20 monoclonal antibody. [electronic resource] - American journal of clinical oncology Aug 2003 - 408-10 p. digital
Publication Type: Case Reports; Journal Article
1537-453X
10.1097/01.COC.0000026485.57632.1E doi
Adult
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Antineoplastic Agents--therapeutic use
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Duodenal Neoplasms--drug therapy
Female
Humans
Lymphoma, Non-Hodgkin--drug therapy
Rituximab
Treatment Failure
Successful treatment of refractory low grade duodenal lymphoma with rituximab, an anti-CD20 monoclonal antibody. [electronic resource] - American journal of clinical oncology Aug 2003 - 408-10 p. digital
Publication Type: Case Reports; Journal Article
1537-453X
10.1097/01.COC.0000026485.57632.1E doi
Adult
Antibodies, Monoclonal--therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Antineoplastic Agents--therapeutic use
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Duodenal Neoplasms--drug therapy
Female
Humans
Lymphoma, Non-Hodgkin--drug therapy
Rituximab
Treatment Failure